Are you routinely offering nivolumab for second-line treatment of small cell lung cancer?
Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemotherapy? If so, do you consider giving ipilimumab in combination with nivo to fit patients?
Answer from: Medical Oncologist at Community Practice
I think that based upon CHECKMATE 032 (Antonia et al Lancet Oncology 2016), we must consider the use of PD-1 inhibition in SCLC. At first glance, the 10% ORR, combined with 22% SD seen with nivolumab monotherapy seems lower than the 23% ORR seen with topotecan, the only FDA approved agent in this s...
Sign in or Register to read more